Neurocrine Biosciences, Inc.

NASDAQ:NBIX   9:50:08 AM EDT
73.96
+1.16 (+1.59%)
Other Pre-Announcement

Neurocrine Biosciences Inc SAYS Ingrezza (Valbenazine) Preliminary Q4 Net Product Sales Of Approximately $301 Million And 56,400 Total Prescriptions

Published: 01/06/2022 21:44 GMT
Neurocrine Biosciences, Inc. (NBIX) - Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-year 2021 Net Product Sales Results and Future Program Milestones.
Neurocrine Biosciences Inc - Ingrezza (valbenazine) Preliminary Q4 Net Product Sales of Approximately $301 Million and 56,400 Total Prescriptions.
Neurocrine Biosciences - Sees Supplemental NDA to U.S. FDA for Valbenazine for Chorea Associated With Huntington Disease Submission in H2 2022.